查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931243

植入式冠状动脉药物洗脱支架市场（依药物类型、代数、聚合物类型、支架材料及适应症划分），全球预测，2026-2032年

Implantable Coronary Drug Eluting Stent Market by Drug Type, Generation, Polymer Type, Stent Material, Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，植入式冠状动脉药物释放型支架市场价值将达到 83.5 亿美元，到 2026 年将成长至 87.1 亿美元，到 2032 年将达到 121.6 亿美元，复合年增长率为 5.51%。

关键市场统计数据
基准年 2025 83.5亿美元
预计年份：2026年 87.1亿美元
预测年份 2032 121.6亿美元
复合年增长率 (%) 5.51%

策略介绍：临床紧迫性、材料科学的进步以及法规环境为推动植入式冠状动脉药物释放型支架的创新和广泛应用提供了框架。

本执行摘要旨在就植入式冠状动脉药物释放型支架展开策略对话，重点在于临床需求、器械工程和商业性动态的交汇点，以指导产品策略和相关人员的决策。降低血管再阻塞和改善长期血管通畅性的干预措施仍然是冠状动脉疾病治疗的重中之重，推动着支架药理学、聚合物科学和支架结构方面的不断改进。随着技术的融合，临床医生和医疗保健系统优先考虑的是持续的临床疗效、易于实施以及与不断发展的抗血小板疗法的兼容性，这些因素将影响采购和应用路径。

分析重塑治疗模式的变革性转变：设备小型化、生物可吸收平台、精准药物治疗和整合数位诊断技术

冠状动脉药物释放型支架领域正经历着由技术、临床和监管因素驱动的变革，重新定义了产品蓝图和临床实践。微型化和精细化的支架几何结构提高了支架在复杂解剖结构中的输送性和贴合性，而抗增殖药物和靶向释放动力学的进步则减少了晚期管腔丢失，并使血管癒合更加可预测。同时，生物可吸收支架和混合支架策略的整合正在推动对长期支架与临时血管支架的评估，这将影响抗血小板治疗的持续时间和追踪影像通讯协定。

评估2025年美国关税政策变化对供应链、成本结构、製造策略和国际采购趋势的累积影响

美国关税调整将于2025年生效，其累积影响将波及整个植入式冠状动脉药物释放型支架价值链，影响原料采购、组件製造及最终组装策略。关税相关的成本压力将促使製造商重新评估其供应商组合，并探索近岸外包和区域内生产，以应对贸易波动并缩短前置作业时间。因此，采购团队必须权衡供应链本地化带来的经济效益与建立符合规范的製造地、检验流程和认证供应路线所需的营运复杂性和投资，以满足严格的品质和监管要求。

整合药物类型、世代週期、聚合物和材料选择以及临床适应症等关键细分洞察，以揭示产品定位和临床差异化优势。

详细的市场区隔分析阐明了产品设计与临床应用如何交汇融合，为器材开发商和临床医生创造差异化的价值提案。基于药物类型，本研究检视了依Everolimus洗脱支架、Sirolimus洗脱支架、西罗莫司洗脱支架和佐他莫司洗脱支架的市场状况。每种类型的药物都具有独特的药物动力学特征、组织相容性考虑以及影响临床选择的历史疗效数据。这些药物差异与器械的世代更迭相互作用。从第一代到第二代再到第三代产品的演进反映了聚合物技术、支架梁厚度和输送系统的改进，这些改进共同影响器械的安全性和传输性能。

整合美洲、欧洲、中东和非洲以及亚太地区的趋势，重点关注市场准入的采用趋势、报销压力和在地化策略

区域趋势将对冠状动脉药物释放型支架的应用模式、报销途径和市场推广策略产生深远影响。在美洲，医疗系统越来越重视比较临床证据和成本效益分析，以支持采购决策，集中采购和打包支付模式正在影响医院的采购决策和术后照护路径。因此，在该地区运营的製造商必须优先建立可靠的临床註册研究和真实世界证据，以满足基于价值的采购要求，并证明其能够降低再入院率和再次手术率。

竞争格局洞察，重点介绍领先设备製造商的策略组合、研发轨迹、伙伴关係模式和商业化路径

冠状动脉药物释放型支架市场的主要企业透过持续的研发投入、策略联盟以及不断累积的临床证据来凸显其优势，这些证据支持其卓越的手术效果和长期安全性。竞争优势越来越依赖能够证明其在输送性、晚期不利事件发生率和手术流程简化方面取得实际改进，从而降低医疗总成本。因此，各机构正将资源投入到薄支架设计、新型合金和优化药物-聚合物基质的研发中，同时与学术机构合作，并透过研究者主导的临床试验和註册研究加速证据的累积。

针对产业领导者的具体策略建议：重点在于监管合规、价值链韧性、临床证据产生和基于价值的商业化策略。

行业领导者必须制定一套连贯的策略，将技术创新与切实可行的商业化和监管计划相结合。首先，他们应优先产生临床证据，这些证据既要涵盖随机对照试验的终点指标，也要涵盖真实世界的疗效指标。这种双管齐下的方法将有助于完善监管申报和与支付方的沟通，同时为差异化产品标籤和临床医生采纳提供参考。其次，他们应透过多元化合格供应商、评估区域或联合生产伙伴关係以及实施流程自动化来增强供应链韧性，从而降低关税和物流波动带来的风险。这些措施将降低营运风险，并确保高需求设施的稳定供应。

严谨的调查方法概述：详细介绍资料来源、相关人员访谈、临床文献综合以及为确保研究结果的可靠性而采用的分析架构。

我们的调查方法结合了系统性的文献回顾、与关键相关人员的直接对话以及结构化的分析框架，以确保获得严谨且切实可行的见解。我们首先对同行评审的临床研究、监管指导文件和技术白皮书进行了全面审查，以梳理现有证据基础并识别安全性和有效性数据方面的不足。在此基础上，我们设计了与各类相关人员，包括介入性心臟病专家、临床负责人、采购主管和生产专家，以提供关于流程需求、实施障碍和营运重点的定性观点。

一份权威的综合分析报告，重点阐述了涂药支架的临床益处、技术进步、监管影响以及持续发展的战略要务。

这个结论综合了分析中涌现的核心讯息：药物选择、聚合物设计和支架结构方面的技术进步正在显着改善支架的输送性和癒合效果；监管机构和支付方越来越要求提供全面的临床证据和清晰的价值证明；供应炼和地缘政治因素，包括关税变化，正在重塑生产和筹资策略。这些趋势要求采用严谨的产品开发方法，将临床检验、业务永续营运和最佳化的市场进入计画结合。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依药物类型植入式冠状动脉药物洗脱支架市场

  • Everolimus洗脱
  • 紫杉醇洗脱
  • Sirolimus洗脱
  • 佐他莫司洗脱

第九章 依世代分類的植入式冠状动脉药物洗脱支架市场

  • 第一代
  • 第二代
  • 第三代

第十章 依聚合物类型分類的植入式冠状动脉药物洗脱支架市场

  • 可生物降解聚合物
  • 耐用聚合物
  • 不含聚合物

第十一章 依支架材质分類的植入式冠状动脉药物洗脱支架市场

  • 钴铬
  • 铂金铬
  • 不銹钢

第十二章植入式冠状动脉药物洗脱支架市场（依适应症划分）

  • 多支血管疾病
  • 非ST段抬高型心肌梗塞
  • ST段上升型心肌梗塞
  • 稳定性心绞痛

第十三章植入式冠状动脉药物洗脱支架市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章植入式冠状动脉药物洗脱支架市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国植入式冠状动脉药物洗脱支架市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国植入式冠状动脉药物洗脱支架市场

第十七章：中国植入式冠状动脉药物洗脱支架市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Alvimedica Medical Technologies Inc.
  • B. Braun Melsungen AG
  • Biosensors International Group, Ltd.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Concept Medical, Inc.
  • Cook Medical Incorporated
  • Hexacath SAS
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medinol Ltd.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • OrbusNeich Medical Group
  • REVA Medical, Inc.
  • Sahajanand Medical Technologies Ltd.
  • SINOMED Co., Ltd.
  • Terumo Corporation
  • Translumina GmbH
Product Code: MRR-7B550E008DDF

The Implantable Coronary Drug Eluting Stent Market was valued at USD 8.35 billion in 2025 and is projected to grow to USD 8.71 billion in 2026, with a CAGR of 5.51%, reaching USD 12.16 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.35 billion
Estimated Year [2026] USD 8.71 billion
Forecast Year [2032] USD 12.16 billion
CAGR (%) 5.51%

Strategic introduction framing the clinical urgency, material science advances, and regulatory environment driving implantable coronary drug eluting stent innovation and adoption

This executive summary opens a strategic conversation about implantable coronary drug eluting stents, emphasizing the intersection of clinical need, device engineering, and commercial dynamics that inform product strategy and stakeholder decision-making. Coronary artery disease management continues to prioritize interventions that reduce restenosis and improve long-term vessel patency, driving ongoing refinement in stent pharmacology, polymer science, and scaffold architecture. As technologies converge, the priorities for clinicians and health systems include durable clinical outcomes, ease of deployment, and compatibility with evolving antiplatelet regimens, which together shape procurement and adoption pathways.

Transitioning from clinical imperatives to market realities, the introduction frames why manufacturers, payers, and provider networks must adapt to a landscape where incremental innovation yields meaningful differences in patient management. In addition, regulatory scrutiny and post-market surveillance expectations are intensifying, prompting device developers to generate robust real-world evidence and to articulate clear value propositions to payers. Consequently, strategic planning for next-generation stent platforms demands an integrated view across R&D, clinical affairs, reimbursement strategy, and supply chain resilience to ensure timely adoption and sustained clinical benefit.

Analysis of transformative shifts including device miniaturization, bioresorbable platforms, precision pharmacotherapy, and integrated digital diagnostics reshaping treatment paradigms

The landscape for coronary drug eluting stents is experiencing transformative shifts driven by technological, clinical, and regulatory forces that are redefining product roadmaps and clinical practice. Miniaturization and refinement of scaffold geometries have improved deliverability and conformability in complex anatomies, while advances in antiproliferative agents and targeted release kinetics have reduced late lumen loss and provided more predictable vascular healing. Simultaneously, the integration of bioresorbable and hybrid scaffold strategies is prompting reassessment of long-term device residency versus temporary vessel support, with implications for antiplatelet therapy duration and follow-up imaging protocols.

In parallel, material science innovations are accelerating the adoption of alternative alloys and thin-strut designs that balance radial strength with reduced vessel injury. Polymer engineering has evolved from durable coatings to biodegradable matrices and polymer-free approaches to mitigate chronic inflammation and late adverse events. These technical shifts are accompanied by a surge in digital health adjuncts, where implantable devices interface with procedural imaging and data platforms to inform precision deployment and longitudinal outcome tracking. Regulatory pathways are adapting to novel materials and combined-device-drug paradigms, requiring sponsors to engage earlier with authorities and to prioritize clinical evidence that demonstrates both safety and comparative effectiveness. Together, these changes are reshaping competitive positioning, clinical trial design, and commercialization strategies across the ecosystem.

Assessment of the cumulative impact of United States tariff policy changes in 2025 on supply chains, cost structures, manufacturing strategies, and transnational procurement dynamics

The cumulative impact of United States tariff adjustments implemented in 2025 reverberates through the implantable coronary drug eluting stent value chain, influencing raw material sourcing, component manufacturing, and final assembly strategies. Tariff-related cost pressures incentivize manufacturers to reassess supplier portfolios and to explore nearshoring or regional manufacturing to buffer against trade volatility and to shorten lead times. Consequently, procurement teams must balance the economic benefits of supply chain localization with the operational complexity and investment required to establish compliant manufacturing sites, validated processes, and qualified supply streams that meet stringent quality and regulatory expectations.

Moreover, tariff-induced input cost increases can alter pricing negotiations with payers and hospital procurement entities, prompting device makers to bolster their value dossiers with stronger clinical evidence, total cost of care analyses, and clear demonstrations of procedure efficiency. In response, some organizations may pursue strategic partnerships or licensing to distribute manufacturing risk, while others will accelerate automation and process optimization to preserve margin. Cross-border regulatory considerations also intensify as manufacturers reorganize production footprints; this, in turn, requires updated device master files, alignment with customs compliance, and proactive engagement with notified bodies and health authorities. Ultimately, the tariff environment underscores the need for resilient commercial strategies, flexible supply chains, and intensified dialogue with stakeholders to maintain access and continuity of care.

Key segmentation insights integrating drug types, generation cycles, polymer and material choices, and clinical indications to illuminate product positioning and clinical differentiation

A nuanced segmentation analysis clarifies how product design and clinical application intersect to create differentiated value propositions for device developers and clinicians. Based on Drug Type, market is studied across Everolimus Eluting, Paclitaxel Eluting, Sirolimus Eluting, and Zotarolimus Eluting, each of which presents distinct pharmacokinetic profiles, tissue compatibility considerations, and historical performance data that influence clinical preference. These drug distinctions interact with device generation; product evolution from First Generation to Second Generation and onward to Third Generation reflects improvements in polymer technologies, stent strut thickness, and delivery systems that collectively impact safety and deliverability.

Polymer considerations remain central to performance, and segmentation by Polymer Type-Biodegradable Polymer, Durable Polymer, and Polymer Free-captures divergent strategies to balance drug elution control with long-term vessel healing. Stent Material segmentation including Cobalt Chromium, Platinum Chromium, and Stainless Steel highlights trade-offs in radiopacity, radial strength, and manufacturability that inform procedural selection in complex anatomies. Finally, clinical Indication segmentation across Multivessel Disease, Non St Elevation Myocardial Infarction, St Elevation Myocardial Infarction, and Stable Angina maps device attributes to therapeutic need, guiding trial design and labeling strategies. By synthesizing these axes of segmentation, stakeholders can identify where clinical differentiation is most compelling and where incremental improvements translate into meaningful clinical or economic benefit.

Regional dynamics synthesized across Americas, Europe, Middle East & Africa, and Asia-Pacific to reveal adoption trends, reimbursement pressures, and localization strategies for market access

Regional dynamics exert a powerful influence on adoption patterns, reimbursement pathways, and strategic go-to-market approaches for coronary drug eluting stents. In the Americas, health systems emphasize comparative clinical evidence and cost-effectiveness analyses to inform procurement, with centralized group purchasing and bundled payment models shaping hospital purchasing decisions and post-procedural care pathways. Manufacturers operating in this region must therefore prioritize robust clinical registries and real-world evidence generation to satisfy value-based procurement requirements and to demonstrate reduced readmissions and repeat interventions.

Across Europe, Middle East & Africa, regulatory harmonization efforts and varied reimbursement frameworks necessitate tailored market access strategies that reflect local HTA processes, national procurement cycles, and differing hospital infrastructures. In several markets within this region, price negotiation and tendering mechanisms are decisive, making comparative clinical data and procedural efficiency metrics central to success. In the Asia-Pacific region, heterogeneous healthcare maturity and rapidly expanding interventional capacity present substantial opportunities, but they also require nuanced approaches to market entry. Local manufacturing partnerships, regional clinical collaborations, and adaptation of training programs for interventional cardiologists are critical to accelerate adoption. Across all regions, alignment of regulatory submissions, post-market surveillance plans, and clinician education initiatives is essential to translate device innovation into sustained patient impact.

Competitive company landscape insights highlighting strategic portfolios, R&D trajectories, partnership models, and commercialization pathways among leading device manufacturers

Leading companies in the coronary drug eluting stent landscape differentiate through sustained investment in R&D, strategic alliances, and the accumulation of clinical evidence that supports superior procedural outcomes and long-term safety. Competitive positioning increasingly hinges on the ability to demonstrate tangible improvements in deliverability, reduced late adverse events, and simplified procedural workflows that lower the total cost of care. Consequently, organizations are allocating resources to thin-strut designs, alternative alloys, and optimized drug-polymer matrices while partnering with academic centers to accelerate evidence generation through investigator-initiated studies and registries.

In addition to product innovation, commercial strategy has become a vital differentiator. Firms are building integrated service models that include proctoring, simulation-based training, and digital platforms to support procedural planning and outcome monitoring. Strategic collaborations with regional manufacturers, contract development and manufacturing organizations, and specialty suppliers are also prevalent, allowing companies to diversify supply lines and to scale production responsively. Finally, mergers and targeted acquisitions continue to play a role in consolidating complementary technologies and expanding therapeutic portfolios, enabling companies to offer comprehensive interventional solutions that meet evolving clinician and patient needs.

Actionable strategic recommendations for industry leaders focused on regulatory alignment, supply chain resilience, clinical evidence generation, and value-based commercialization strategies

Industry leaders should pursue a cohesive strategy that aligns technological innovation with pragmatic commercialization and regulatory planning. First, prioritize clinical evidence generation that addresses both randomized controlled endpoints and real-world effectiveness measures; this dual approach strengthens regulatory submissions and payer dialogues while delivering insights that support differentiated labeling and clinician adoption. Second, invest in supply chain resilience by diversifying qualified suppliers, evaluating regional manufacturing or co-manufacturing partnerships, and implementing process automation to mitigate tariff and logistics volatility. These measures reduce operational risk and enable more predictable fulfillment for high-volume centers.

Third, adopt a value-based commercialization model that links product claims to procedural efficiency, patient outcomes, and downstream cost reductions. This involves developing robust health economic dossiers, engaging early with HTA bodies, and collaborating with hospitals to pilot bundled care pathways. Fourth, accelerate clinician training and support through immersive simulation, proctorship programs, and integrated data platforms that enhance procedural planning and post-procedural surveillance. Finally, maintain proactive regulatory engagement, anticipating evolving requirements for combination product evaluation and real-world evidence commitments. By implementing these integrated actions, organizations can preserve competitiveness while advancing patient-centered outcomes.

Rigorous research methodology overview detailing data sources, stakeholder interviews, clinical literature synthesis, and analytical frameworks employed to ensure robust findings

The research methodology combines systematic literature synthesis, primary stakeholder engagement, and structured analytical frameworks to ensure rigorous and actionable insights. The approach began with comprehensive review of peer-reviewed clinical studies, regulatory guidance documents, and technical white papers to map the current evidence base and to identify gaps in safety and effectiveness data. This secondary research informed the design of targeted interviews with a cross-section of stakeholders, including interventional cardiologists, clinical trialists, procurement leaders, and manufacturing experts, providing qualitative perspectives on procedural needs, adoption barriers, and operational priorities.

Quantitative inputs were derived from device performance registries, procedural utilization databases, and publicly available regulatory filings to triangulate clinical outcomes and device characteristics. The analysis applied comparative effectiveness frameworks and value-assessment methodologies to evaluate how design features translate into clinical and economic benefits. Throughout the study, the team employed iterative validation, presenting preliminary findings to a panel of clinical advisors and industry stakeholders to refine interpretations and to ensure relevance to real-world decision-making. This transparent and multi-modal methodology underpins the report's recommendations and supports their practical application.

Conclusive synthesis emphasizing clinical benefit, technological momentum, regulatory implications, and strategic imperatives for sustained advancement of drug eluting stents

The conclusion synthesizes the core messages that emerged from the analysis: technological refinements in drug selection, polymer engineering, and scaffold architecture are delivering clinically meaningful improvements in deliverability and healing profiles; regulatory and payer environments increasingly demand comprehensive clinical evidence and clear demonstrations of value; and supply chain and geopolitical forces, including tariff changes, are reshaping manufacturing and procurement strategies. Together, these dynamics call for a disciplined approach to product development that integrates clinical validation, operational resilience, and tailored market access planning.

Looking ahead, successful stakeholders will be those that translate technical innovation into quantifiable clinical and economic benefits, maintain agile manufacturing footprints, and cultivate sustained clinician partnerships that support training and evidence generation. By aligning R&D priorities with payer and provider needs, and by investing in the infrastructure necessary to demonstrate real-world value, organizations can both improve patient outcomes and secure durable market positions. This balanced focus on science, evidence, and commercial execution defines the pathway for long-term success in the evolving implantable coronary drug eluting stent domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Implantable Coronary Drug Eluting Stent Market, by Drug Type

  • 8.1. Everolimus Eluting
  • 8.2. Paclitaxel Eluting
  • 8.3. Sirolimus Eluting
  • 8.4. Zotarolimus Eluting

9. Implantable Coronary Drug Eluting Stent Market, by Generation

  • 9.1. First Generation
  • 9.2. Second Generation
  • 9.3. Third Generation

10. Implantable Coronary Drug Eluting Stent Market, by Polymer Type

  • 10.1. Biodegradable Polymer
  • 10.2. Durable Polymer
  • 10.3. Polymer Free

11. Implantable Coronary Drug Eluting Stent Market, by Stent Material

  • 11.1. Cobalt Chromium
  • 11.2. Platinum Chromium
  • 11.3. Stainless Steel

12. Implantable Coronary Drug Eluting Stent Market, by Indication

  • 12.1. Multivessel Disease
  • 12.2. Non St Elevation Myocardial Infarction
  • 12.3. St Elevation Myocardial Infarction
  • 12.4. Stable Angina

13. Implantable Coronary Drug Eluting Stent Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Implantable Coronary Drug Eluting Stent Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Implantable Coronary Drug Eluting Stent Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Implantable Coronary Drug Eluting Stent Market

17. China Implantable Coronary Drug Eluting Stent Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Alvimedica Medical Technologies Inc.
  • 18.7. B. Braun Melsungen AG
  • 18.8. Biosensors International Group, Ltd.
  • 18.9. Biotronik SE & Co. KG
  • 18.10. Boston Scientific Corporation
  • 18.11. Concept Medical, Inc.
  • 18.12. Cook Medical Incorporated
  • 18.13. Hexacath S.A.S.
  • 18.14. Lepu Medical Technology (Beijing) Co., Ltd.
  • 18.15. Medinol Ltd.
  • 18.16. Medtronic plc
  • 18.17. Meril Life Sciences Pvt. Ltd.
  • 18.18. MicroPort Scientific Corporation
  • 18.19. OrbusNeich Medical Group
  • 18.20. REVA Medical, Inc.
  • 18.21. Sahajanand Medical Technologies Ltd.
  • 18.22. SINOMED Co., Ltd.
  • 18.23. Terumo Corporation
  • 18.24. Translumina GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY ZOTAROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY ZOTAROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY ZOTAROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COBALT CHROMIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COBALT CHROMIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COBALT CHROMIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY PLATINUM CHROMIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY PLATINUM CHROMIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY PLATINUM CHROMIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY MULTIVESSEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY MULTIVESSEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY MULTIVESSEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY NON ST ELEVATION MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY NON ST ELEVATION MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY NON ST ELEVATION MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY ST ELEVATION MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY ST ELEVATION MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY ST ELEVATION MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 117. GCC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. GCC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 119. GCC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 135. G7 IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. G7 IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 137. G7 IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. NATO IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 141. NATO IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NATO IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. NATO IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)